€10.60
1.92% day before yesterday
Madrid, Nov 22, 05:38 pm CET
ISIN
ES0171996087
Symbol
GRF
Sector
Industry

Grifols Stock price

€10.60
+0.43 4.23% 1M
+1.33 14.37% 6M
-4.86 31.41% YTD
-2.11 16.60% 1Y
-6.96 39.62% 3Y
-19.40 64.67% 5Y
-7.33 40.87% 10Y
Madrid, Closing price Fri, Nov 22 2024
+0.20 1.92%
ISIN
ES0171996087
Symbol
GRF
Sector
Industry

Key metrics

Market capitalization €7.20b
Enterprise Value €18.43b
P/E (TTM) P/E ratio 45.83
EV/Sales (TTM) EV/Sales 2.80
P/S ratio (TTM) P/S ratio 1.10
P/B ratio (TTM) P/B ratio 1.29
Revenue growth (TTM) Revenue growth 8.71%
Revenue (TTM) Revenue €6.57b
EBIT (operating result TTM) EBIT €857.73m
Free Cash Flow (TTM) Free Cash Flow €-1.26m
Cash position €644.94m
EPS (TTM) EPS €0.23
P/E forward 31.04
P/S forward 1.01
EV/Sales forward 2.60
Show more

Is Grifols a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Grifols Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Grifols forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Grifols forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Grifols

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
6,573 6,573
8% 8%
100%
- Direct Costs 4,072 4,072
3% 3%
62%
2,501 2,501
19% 19%
38%
- Selling and Administrative Expenses 810 810
17% 17%
12%
- Research and Development Expense 392 392
24% 24%
6%
1,300 1,300
19% 19%
20%
- Depreciation and Amortization 442 442
8% 8%
7%
EBIT (Operating Income) EBIT 858 858
26% 26%
13%
Net Profit 157 157
25% 25%
2%

In millions EUR.

Don't miss a Thing! We will send you all news about Grifols directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,744
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today